CN107405397B - 抗tim-3抗体 - Google Patents

抗tim-3抗体 Download PDF

Info

Publication number
CN107405397B
CN107405397B CN201580071169.9A CN201580071169A CN107405397B CN 107405397 B CN107405397 B CN 107405397B CN 201580071169 A CN201580071169 A CN 201580071169A CN 107405397 B CN107405397 B CN 107405397B
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
ser
tim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580071169.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107405397A (zh
Inventor
汪正一
胡雪玲
杨淑斌
吴云佩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201419089A external-priority patent/GB201419089D0/en
Priority claimed from GB201419092A external-priority patent/GB201419092D0/en
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Priority to CN201910641759.0A priority Critical patent/CN110294807B/zh
Publication of CN107405397A publication Critical patent/CN107405397A/zh
Application granted granted Critical
Publication of CN107405397B publication Critical patent/CN107405397B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/7051—T-cell receptor (TcR)-CD3 complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580071169.9A 2014-10-27 2015-10-27 抗tim-3抗体 Active CN107405397B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910641759.0A CN110294807B (zh) 2014-10-27 2015-10-27 抗tim-3抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1419089.6 2014-10-27
GB1419092.0 2014-10-27
GB201419089A GB201419089D0 (en) 2014-10-27 2014-10-27 Anti-TIM-3 antibodies
GB201419092A GB201419092D0 (en) 2014-10-27 2014-10-27 Anti-TIM-3 antibodies
PCT/SG2015/050415 WO2016068803A1 (en) 2014-10-27 2015-10-27 Anti-tim-3 antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910641759.0A Division CN110294807B (zh) 2014-10-27 2015-10-27 抗tim-3抗体

Publications (2)

Publication Number Publication Date
CN107405397A CN107405397A (zh) 2017-11-28
CN107405397B true CN107405397B (zh) 2020-08-25

Family

ID=55857945

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580071169.9A Active CN107405397B (zh) 2014-10-27 2015-10-27 抗tim-3抗体
CN201910641759.0A Active CN110294807B (zh) 2014-10-27 2015-10-27 抗tim-3抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910641759.0A Active CN110294807B (zh) 2014-10-27 2015-10-27 抗tim-3抗体

Country Status (9)

Country Link
US (2) US10259874B2 (enExample)
EP (1) EP3212231B1 (enExample)
JP (1) JP6709215B2 (enExample)
KR (1) KR20170075778A (enExample)
CN (2) CN107405397B (enExample)
AU (1) AU2015340056A1 (enExample)
CA (1) CA2965960A1 (enExample)
SG (2) SG11201703403TA (enExample)
WO (1) WO2016068803A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201419094D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
SG11201703403TA (en) 2014-10-27 2017-05-30 Agency Science Tech & Res Anti-tim-3 antibodies
EP3265486A4 (en) * 2015-03-06 2018-11-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
WO2017031242A1 (en) * 2015-08-20 2017-02-23 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
MA45123A (fr) * 2016-05-27 2019-04-10 Agenus Inc Anticorps anti-tim-3 et leurs méthodes d'utilisation
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
AU2017297506A1 (en) * 2016-07-14 2019-02-21 Bristol-Myers Squibb Company Antibodies against TIM3 and uses thereof
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
WO2018036561A1 (en) 2016-08-26 2018-03-01 Beigene, Ltd. Anti-tim-3 antibodies and use thereof
US11479600B2 (en) * 2016-10-21 2022-10-25 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
SG11201903287PA (en) 2016-10-21 2019-05-30 Adimab Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
CN108264557B (zh) * 2016-12-30 2021-08-24 惠和生物技术(上海)有限公司 一种结合cd3和t细胞负共刺激分子的双功能分子及其应用
EP3565598A4 (en) * 2017-01-03 2020-10-28 Trellis Bioscience, LLC NATIVE HUMAN ANTIBODIES FOR TIM-3 AND B7-H3 IMMUNE CHECKPOINT MODULATION TARGETS
WO2018140821A1 (en) 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
EP3658185A4 (en) 2017-07-28 2021-07-14 Phanes Therapeutics, Inc. ANTI-TIM-3 ANTIBODIES AND USES THEREOF
WO2019046321A1 (en) 2017-08-28 2019-03-07 Bristol-Myers Squibb Company TIM-3 ANTAGONISTS FOR THE TREATMENT AND DIAGNOSIS OF CANCERS
CN118373912A (zh) 2017-11-10 2024-07-23 新加坡科技研究局 IL2Rβ/共同γ链抗体
KR102813913B1 (ko) * 2018-01-12 2025-05-30 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
WO2019143607A1 (en) 2018-01-16 2019-07-25 Bristol-Myers Squibb Company Methods of treating cancer with antibodies against tim3
WO2019165982A1 (en) 2018-02-28 2019-09-06 WuXi Biologics Ireland Limited Monoclonal antibody against human lag-3, method for preparing same, and use thereof
CN110272489B (zh) * 2018-03-15 2023-08-22 上海健信生物医药科技有限公司 一种针对tim-3的全人源化抗体分子, 抗原结合片段及其医药用途
CN110305216B (zh) * 2018-03-20 2022-09-02 无锡智康弘义生物科技有限公司 新型抗tim-3抗体
JP7351845B2 (ja) 2018-03-23 2023-09-27 ブリストル－マイヤーズ スクイブ カンパニー Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用
WO2019196911A1 (en) * 2018-04-12 2019-10-17 Nanjing Leads Biolabs Co., Ltd. Antibody binding tim-3 and use thereor
AU2019258468B2 (en) * 2018-04-24 2023-06-29 Ampsource Biopharma Shanghai Inc. Antibody against TIM-3 and application thereof
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
EA202190056A1 (ru) * 2018-06-19 2021-05-28 Ридженерон Фармасьютикалз, Инк. АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ
AU2019301633A1 (en) 2018-07-09 2021-01-28 Surrozen Operating, Inc. Tissue-specific Wnt signal enhancing molecules and uses
JP2022505925A (ja) * 2018-11-01 2022-01-14 メルク パテント ゲーエムベーハー 抗ｔｉｍ－３抗体
WO2020094836A1 (en) 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
WO2020094834A1 (en) 2018-11-09 2020-05-14 Euchloe Bio Pte. Ltd. Il2rbeta/common gamma chain antibodies
EP3876988A4 (en) * 2018-11-09 2022-11-09 Beth Israel Deaconess Medical Center THERAPIES TARGETED AGAINST CDCP1
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2020243570A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Cell localization signature and combination therapy
US20220363760A1 (en) 2019-05-30 2022-11-17 Bristol-Myers Squibb Company Multi-tumor gene signature for suitability to immuno-oncology therapy
JP2022534982A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
CN110498855A (zh) * 2019-07-25 2019-11-26 钟小泉 一种tim-3抗体及其用途
CN110922478B (zh) * 2019-12-07 2021-07-30 中国人民解放军军事科学院军事医学研究院 针对特异表位的抗基孔肯雅热的全人源单克隆抗体及应用
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2021169948A1 (zh) * 2020-02-24 2021-09-02 苏州恒康生命科学有限公司 Tim3结合分子及其应用
KR102536302B1 (ko) * 2020-02-25 2023-05-26 국립암센터 Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도
US20230355804A1 (en) 2020-06-29 2023-11-09 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
EP4204453A1 (en) 2020-08-31 2023-07-05 Bristol-Myers Squibb Company Cell localization signature and immunotherapy
CN112094348B (zh) * 2020-09-22 2021-11-30 首都医科大学附属北京胸科医院 抗人Tim3抗体或其功能性片段及其应用
JP2023549854A (ja) 2020-11-16 2023-11-29 スロゼン オペレーティング， インコーポレイテッド 肝臓特異的Ｗｎｔシグナル増強分子およびその使用
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
US20220233689A1 (en) 2020-12-28 2022-07-28 Bristol-Myers Squibb Company Methods of treating tumors
RS66849B1 (sr) 2020-12-28 2025-06-30 Bristol Myers Squibb Co Kompozicije antitela i postupci njihove upotrebe
CA3208935A1 (en) * 2021-01-22 2022-07-28 Elpis Biopharmaceuticals Bispecific chimeric antigen receptors binding to cd19 and cd22
EP4083065A1 (en) 2021-01-28 2022-11-02 NantBio, Inc. Anti-tim3 monoclonal antibodies and chimeric antigen receptors
CA3214085A1 (en) 2021-03-31 2022-10-06 Darby Rye Schmidt Thanotransmission polypeptides and their use in treating cancer
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
KR20240026507A (ko) 2021-06-29 2024-02-28 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도
CN114181311B (zh) * 2021-12-20 2023-06-20 华东师范大学 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用
WO2023168195A2 (en) * 2022-03-04 2023-09-07 The Scripps Research Institute Human broadly neutralizing antibodies against betacoronaviruses
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
CN102492038A (zh) * 2011-12-09 2012-06-13 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CN103079644A (zh) * 2010-06-11 2013-05-01 协和发酵麒麟株式会社 抗tim-3抗体
CN103936853A (zh) * 2014-01-26 2014-07-23 中国人民解放军军事医学科学院基础医学研究所 一种检测tim-3试剂盒及其使用方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258726A1 (en) 1995-06-14 2010-12-08 The Regents of the University of California High affinity human antibodies to c-erbB-2
US20030103978A1 (en) 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
ES2192426B1 (es) 2000-05-11 2005-02-16 Universidad De Vigo Anticuerpo monoclonal humano sm50/20 que reconoce leucocitos humanos, y su uso en terapia.
JP4754219B2 (ja) 2002-12-02 2011-08-24 アムジエン・フレモント・インコーポレイテツド 腫瘍壊死因子を対象とする抗体、およびそれらの使用
JP2007525434A (ja) 2003-03-19 2007-09-06 アブジェニックス インコーポレイテッド Ｔ細胞、免疫グロブリンドメインおよびムチンドメイン１（ｔｉｍ−１）抗原に対する抗体およびその使用。
BRPI0414924A (pt) * 2003-10-03 2006-11-07 Brigham & Womens Hospital ligantes de tim-3 e seus métodos
PT2100614E (pt) 2005-06-17 2013-12-16 Imclone Llc Antagonistas de receptor para tratamento de cancro ósseo metastático
CA2629453C (en) 2005-11-10 2018-03-06 Curagen Corporation Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
US20110059106A1 (en) * 2008-01-29 2011-03-10 Brigham And Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
US9000131B2 (en) 2008-07-31 2015-04-07 The Regents Of The University Of California Antibodies that neutralize botulinum neurotoxins
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8647623B2 (en) 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
JP2013523184A (ja) 2010-04-15 2013-06-17 アムジエン・インコーポレーテツド ヒトＦＧＦ受容体およびβ−ＫＬＯＴＨＯ結合性タンパク質
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2543680A1 (en) * 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
CN102392038B (zh) 2011-11-01 2013-04-17 浙江大学 一种删除转基因水稻精米中的外源基因的表达载体及其应用
CA2916638C (en) 2012-07-31 2021-01-12 The Brigham And Women's Hospital, Inc. Modulation of the immune response
AU2013302696B9 (en) * 2012-08-14 2018-08-09 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
CN103665164A (zh) * 2012-10-24 2014-03-26 中国人民解放军军事医学科学院基础医学研究所 一种检测Tim-3的ELISA试剂盒
WO2014070874A1 (en) 2012-10-31 2014-05-08 The Brigham And Women's Hospital, Inc. Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
JP2014162739A (ja) * 2013-02-22 2014-09-08 National Institute Of Biomedical Innovation 二重特異性抗体及び医薬組成物
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
SG11201703403TA (en) 2014-10-27 2017-05-30 Agency Science Tech & Res Anti-tim-3 antibodies
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
CN104592388B (zh) * 2015-03-02 2017-05-31 中国人民解放军总医院 一种抗人Tim‑3的单克隆抗体的抗原结合部分

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103079644A (zh) * 2010-06-11 2013-05-01 协和发酵麒麟株式会社 抗tim-3抗体
WO2011159877A2 (en) * 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CN102492038A (zh) * 2011-12-09 2012-06-13 中国人民解放军军事医学科学院基础医学研究所 抗人Tim-3的中和性单克隆抗体L3D及其用途
CN103936853A (zh) * 2014-01-26 2014-07-23 中国人民解放军军事医学科学院基础医学研究所 一种检测tim-3试剂盒及其使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Thl细胞特异性表面分子TIM-3研究进展;张胜桃 等;《中华风湿病学杂志》;20070930;第11卷(第9期);第564-566页 *
Tim-3 抗体的生物学活性及应用研究;侯春梅 等;《军事医学》;20140831;第38卷(第8期);第617-620页 *
Tim-3及其配体Galectin-9与病毒感染的关系;赵慧 等;《基础医学与临床》;20120930;第32卷(第9期);第1095-1096页 *
T细胞免疫球蛋白粘蛋白家族Tim-3分子与肿瘤免疫;金璐 等;《国际免疫学杂志》;20130131;第36卷(第1期);第28-31页 *
T细胞免疫球蛋白黏蛋白分子3与慢性病毒感染;任劲松 等;《国际流行病学传染病学杂志》;20110228;第38卷(第1期);第48-50页 *

Also Published As

Publication number Publication date
CA2965960A1 (en) 2016-05-06
US20190185564A1 (en) 2019-06-20
CN107405397A (zh) 2017-11-28
JP2017536111A (ja) 2017-12-07
WO2016068803A1 (en) 2016-05-06
EP3212231A1 (en) 2017-09-06
EP3212231A4 (en) 2018-03-28
AU2015340056A1 (en) 2017-05-25
US11142574B2 (en) 2021-10-12
JP6709215B2 (ja) 2020-06-10
EP3212231B1 (en) 2021-04-28
US10259874B2 (en) 2019-04-16
CN110294807A (zh) 2019-10-01
US20170240633A1 (en) 2017-08-24
KR20170075778A (ko) 2017-07-03
CN110294807B (zh) 2023-05-12
SG11201703403TA (en) 2017-05-30
SG10201803042PA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
CN107405397B (zh) 抗tim-3抗体
CN107530420B (zh) 抗tim-3抗体
CN107428832B (zh) 抗pd-l1抗体
CN107438621B (zh) 抗pd-1抗体
CN109563165B (zh) 抗ctla-4抗体
KR20180114218A (ko) 항-lag-3 항체
CN110603267A (zh) 与p53-MHC I类复合物结合的T细胞受体样抗体
HK40000388A (en) Anti-ctla-4 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant